150 Participants Needed

Geriatric Assessment for Cancer in Seniors with Frailty or Cognitive Impairment

RS
ET
DH
Overseen ByDamsadie Hannedige, BSc, MSc
Age: 65+
Sex: Any
Trial Phase: Academic
Sponsor: Nova Scotia Health Authority
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 3 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores the effects of geriatric assessment on seniors with frailty or cognitive impairment undergoing elective cancer surgery. The goal is to determine if a specialized pre-surgery assessment at the PATH clinic can help patients spend more time at home six months post-surgery. Participants will receive either the usual pre-surgery care or the enhanced assessment at the PATH clinic. Seniors aged 75 and older, scheduled for cancer surgery, and experiencing mild or greater frailty with cognitive issues or moderate frailty with other health conditions, are well-suited for this trial. As an unphased trial, this study offers participants the chance to contribute to innovative research that could enhance pre-surgery care for seniors.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that this geriatric assessment is safe for seniors with frailty or cognitive impairment?

Research shows that geriatric assessments are generally safe and manageable for older adults. These assessments help researchers understand an older person's health needs by examining both medical and social aspects. They have been used for older adults, especially those with cancer, without major reports of harm from the assessment itself.

Since this trial includes geriatric assessment as part of the treatment, the safety evidence from previous research is important. Geriatric assessments do not involve drugs or invasive procedures. Instead, they focus on understanding the patient's health to guide treatment, making them a low-risk option for participants.12345

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores a geriatric assessment approach specifically tailored for seniors with frailty or cognitive impairment who are undergoing cancer treatment. Unlike the standard preoperative assessments, which are more general and include standard internal medicine and anesthesia evaluations, the PATH geriatric care arm offers a specialized assessment through a dedicated geriatric clinic. This method aims to better address the unique challenges and needs of older cancer patients, potentially improving their outcomes by personalizing their care plan. By focusing on a more comprehensive understanding of the patients' health status, the PATH clinic approach seeks to optimize preoperative care, enhancing both safety and quality of life for these vulnerable individuals.

What evidence suggests that geriatric assessment is effective for cancer surgery in seniors with frailty or cognitive impairment?

Research shows that a thorough health check-up for older adults with cancer, known as a comprehensive geriatric assessment (CGA), can be beneficial. Studies have found that CGA improves the quality of life for seniors, particularly 3 and 12 months after treatment. Although it might not significantly reduce overall death rates, it has been linked to fewer deaths at a 6-month follow-up. These assessments help frail older patients by addressing their specific medical needs. This approach allows doctors to customize treatment for each person's health conditions, leading to better results. Participants in this trial will either receive the standard of care or undergo the PATH geriatric care, which includes a pre-operative assessment through the PATH clinic.16789

Who Is on the Research Team?

RS

Richard Spence, MD, FRCSC

Principal Investigator

Queen Elizabeth II Health Sciences Center

Are You a Good Fit for This Trial?

This trial is for patients aged 75 or older who are scheduled for elective cancer surgery and have been identified as severely frail or cognitively impaired. They must consent to the surgery, not live in long-term care before their diagnosis, and cannot be urgent/emergent cases.

Inclusion Criteria

Informed consent for participation must be received
I have a confirmed diagnosis of cancer in the lung, throat, bone, reproductive organs, breast, or digestive system.
I am considered frail due to cognitive issues or physical health conditions.
See 2 more

Exclusion Criteria

Urgent/emergent cases are excluded.
Patients cannot be a resident in a long-term care facility prior to the cancer diagnosis

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Preoperative Assessment

Participants undergo either standard preoperative assessment or PATH geriatric care assessment

1-2 weeks
1 visit (in-person)

Surgery and Immediate Postoperative Care

Participants undergo cancer surgery and receive immediate postoperative care

1-2 weeks

Follow-up

Participants are monitored for safety and effectiveness after surgery, including assessment of time spent at home and other outcomes

6 months

What Are the Treatments Tested in This Trial?

Interventions

  • Geriatric assessment
Trial Overview The study compares standard preoperative care with a specialized geriatric assessment at the PATH clinic for elderly patients facing cancer surgery. The main goal is to see if this approach helps them spend more time at home after six months post-surgery.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: PATH geriatric careExperimental Treatment1 Intervention
Group II: Standard of careActive Control1 Intervention

Geriatric assessment is already approved in Canada, European Union, United States for the following indications:

🇨🇦
Approved in Canada as Geriatric Assessment for:
🇪🇺
Approved in European Union as Comprehensive Geriatric Assessment for:
🇺🇸
Approved in United States as Geriatric Assessment for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Nova Scotia Health Authority

Lead Sponsor

Trials
302
Recruited
95,300+

Published Research Related to This Trial

In a study of 282 elderly cancer patients, the SAOP2 screening tool demonstrated better sensitivity for identifying frailty compared to the G8 tool, with an area under the curve (AUC) of 0.85 versus 0.79.
Both screening tools effectively identified frailty, but SAOP2 was particularly effective in breast cancer patients and those aged 70-80, indicating its potential for better clinical application in routine practice.
Predictive values of two frailty screening tools in older patients with solid cancer: a comparison of SAOP2 and G8.Russo, C., Giannotti, C., Signori, A., et al.[2022]
A study involving 494 elderly cancer patients (median age 75) found that three specific items from the Mini Nutritional Assessment (MNA) can predict the feasibility of chemotherapy, helping to streamline patient assessments.
The Geriatric Prognostic Index (GPI), based on three items, effectively identifies elderly patients at higher risk for mortality, with increasing hazard ratios indicating greater risk with more positive items.
Prognostic factors for the feasibility of chemotherapy and the Geriatric Prognostic Index (GPI) as risk profile for mortality before chemotherapy in the elderly.Aaldriks, AA., Maartense, E., Nortier, HJ., et al.[2022]
The comprehensive geriatric assessment (CGA) utilized various tests to evaluate the health and functional status of older cancer patients, highlighting areas of limitation in their care.
Most CGA recommendations focused on general cancer treatment strategies, with additional emphasis on fall prevention and education, indicating a holistic approach to managing the health of elderly patients in oncology.
Comprehensive Geriatric Assessment: Interprofessional Team Recommendations for Older Adult Women With Breast CancerOvercash, J.[2019]

Citations

The effectiveness of comprehensive geriatric assessment ...Very low-quality evidence suggested improved quality of life in the CGA group at 3 and 12 months, as reported by Cohen (2002) and Puts (2018).
Effectiveness of comprehensive geriatric assessment in ...CGA did not significantly reduce overall mortality in frail older inpatients compared to usual care but lowered mortality rates at the 6-month follow-up.
The value and effectiveness of geriatric assessments for ...GAs seems to be beneficial for older adults with cancer across some outcomes, with strong evidence demonstrating the impact of GA with management for treatment ...
Comprehensive geriatric assessment - UpToDateComprehensive geriatric assessment (CGA) is defined as a multidisciplinary diagnostic and treatment process that identifies medical, ...
The value and effectiveness of geriatric assessments for older ...GAs seems to be beneficial for older adults with cancer across some outcomes, with strong evidence demonstrating the impact of GA with management for treatment ...
Comprehensive geriatric assessment for older adults admitted ...CGA is a multi‐dimensional diagnostic and therapeutic process that is focused on determining a frail older person's medical, functional, mental, and social ...
The effect of comprehensive geriatric assessment on care ...This systematic review seeks to evaluate the impact of a 'GA with intervention' or CGA (GA/CGA) on outcomes for older adults with cancer receiving systemic ...
Comprehensive geriatric assessment for patients with cancerINTRODUCTION. Approximately 54 percent of new cases and 70 percent of mortality from cancer occur in patients ≥65 years of age [1,2].
Frailty and Cancer: Current Perspectives on Assessment ...This review describes the current standards and perspectives for the assessment and monitoring of frailty in elderly patients with cancer.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security